News

The vaccination campaign organised by the UAB Healthcare Service will offer the Tetanus Diphtheria Vaccine to university community member aged over 40.

The Alzheimer’s Association will fund UAB projects studying the molecular alterations of inhibitory neurons which take place in patients with Alzheimer's.

Researchers from the IBB-UAB have developed a new class of nanostructures capable of trapping and neutralising large quantities of the SARS-CoV-2 virus particles, both in liquid solutions and on the surface of materials. These novel nanoparticles could be used to manufacture antiviral materials such as wastewater and air filters, and could be exploited to develop new tests for the early detection of COVID-19. Moreover, the nanoparticles could be redesigned to target other pathogens.

UAB researchers have reversed metabolic dysfunction-associated steatohepatitis (MASH) in mouse models. MASH is a severe liver disease associated with obesity and type 2 diabetes that affects more than 40 million people. The results were obtained with a single intramuscular administration of the therapeutic viral vectors. The research has also determined that most obese, type 2 diabetic and MASH patients could benefit from the therapy. The results will be the basis for a future clinical trial by the biopharmaceutical company Kriya